Cited by 727Liver Disease Diagnosis and TreatmentLiver Diseases and ImmunityAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial

Open access

Lindor, Keith D., Kowdley, Kris V., Heathcote, Jenny E., Harrison, Edwyn M., Jorgensen, Roberta, Angulo, Paul, Lymp, James F., Burgart, Lawrence, Colin, Patrick·2004·Hepatology

DOI 10.1002/hep.20092

Open this paper in CoChat — free account Open PDF

Abstract

No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinical studies. We randomized 166 patients with liver biopsy-proven NASH to receive between 13 and 15 mg/kg/d of UDCA or placebo for 2 years. End points included changes in liver test results and liver histology at 2 years of therapy. The treatment groups were comparable at entry with regard to age, gender, risk factors for NASH, serum liver biochemistries, and baseline liver histology. A total of 126 patients completed 2 years of therapy. Pre- and posttreatment liver biopsies were available in 107 patients for review at the end of the study. UDCA was well tolerated and body weight was stable during the study duration. Serum liver biochemistries were stable or improved in both the UDCA and placebo-treated groups. Changes in the degree of steatosis, necroinflammation, or fibrosis that occurred with therapy were not significantly different between the UDCA and placebo groups. In conclusion, 2 years of therapy with UDCA at a dose of 13 to 15 mg/kg/d, although safe and well tolerated, is not better than placebo for patients with NASH.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/hep.20092

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Self-citation
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Nonalcoholic Steatohepatitis
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234
Reversal of Obesity- and Diet-Induced Insulin Resistance with Salicylates or Targeted Disruption of Ikkβ
Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.-W., Karin, M., & Shoelson, S. E. (2001) · Science · doi:10.1126/science.1061620 · Cited by 1,884
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K., & Lindor, K. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,708
Self-citation
Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., CARUCCI, P., Musso, A., Paolis, P. D., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,436
Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy
Bellentani, S., Saccoccio, G., Masutti, F., Crocè, L. S., Brandi, G., Sasso, F., Cristanini, G., & Tiribelli, C. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-2-200001180-00004 · Cited by 1,267
Nonalcoholic fatty liver disease
Clark, J. M., Brancati, F. L., & Diehl, A. M. (2002) · Gastroenterology · doi:10.1053/gast.2002.33573 · Cited by 929

Flagged first, then by citations

Show all 26 references

Research works printed but not linked: 2

Neuschwander-Tetri, 2002, Histological improvement in NASH following reduction in insulin resistance with 48-week treatment with PPAR agonist rosiglitazone. abstract., HEPATOLOGY, 36, 379A
Kobak, 2002, Fat-laden hepatocytes are more prone to cellular necrosis than apoptosis when exposed to hydrophobic bile acids., Gastroenterology, 122, A642

Sorted by citations

Items 301–400 of 727

Liver biopsy in alcoholic and non-alcoholic steatohepatitis patients
TINIAKOS, D. G. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2009.05.009 · Cited by 39
Nonalcoholic fatty liver disease in children living in the obeseogenic society
A‐Kader, H. H. (2009) · World Journal of Pediatrics · doi:10.1007/s12519-009-0048-8 · Cited by 39
Non-alcoholic fatty liver disease: A review with clinical and pathological correlation
Chen, Y., & Yeh, M. M. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.07.006 · Cited by 39
Rosiglitazone Attenuates Liver Inflammation in a Rat Model of Nonalcoholic Steatohepatitis
Tahan, V., Eren, F., Avşar, E., Yavuz, D. G., Yüksel, M., Emekli, E., İmeryüz, N., Çelikel, Ç., Uzun, H., Haklar, G., et al. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-9756-x · Cited by 39
Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis
Le, T., & Loomba, R. S. (2012) · Journal of Clinical and Experimental Hepatology · doi:10.1016/s0973-6883(12)60104-2 · Cited by 41
Medical Treatment of Non-alcoholic Steatohepatitis
Kadayıfçı, A., Merriman, R. B., & Bass, N. M. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.02.001 · Cited by 38
Bile Formation and the Enterohepatic Circulation
Dawson, P. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382026-6.00053-1 · Cited by 39
Treatment of patients with non-alcoholic fatty liver disease: Current views and perspectives
Federico, A., Trappoliere, M., & Loguercio, C. (2006) · Digestive and Liver Disease · doi:10.1016/j.dld.2006.04.009 · Cited by 38
Strategies to optimize the use of marginal donors in liver transplantation
Pezzati, D. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i26.2636 · Cited by 38
Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis
Ratziu, V., Ghabril, M., Romero‐Gómez, M., & Svegliati‐Baroni, G. (2018) · Transplantation · doi:10.1097/tp.0000000000002483 · Cited by 40
Effect of ursodeoxycholic acid on liver markers: A systematic review and meta‐analysis of randomized placebo‐controlled clinical trials
Simental-Mendía, M. A., Sánchez‐García, A., & Simental‐Mendía, L. E. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14311 · Cited by 45
Second World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1821 · Cited by 37
Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets
Cheng, Z., Chen, Y., Schnabl, B., Chu, H., & Yang, L. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.06.009 · Cited by 41
Fatty Liver and Liver Transplantation
Koehler, E. M., Watt, K. D. S., & Charlton, M. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.010 · Cited by 37
Approach to the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease
Ong, J. P., & Younossi, Z. M. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2005.07.002 · Cited by 37
Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease
Steinacher, D., Claudel, T., & Trauner, M. (2017) · Digestive Diseases · doi:10.1159/000454853 · Cited by 38
N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL
de Oliveira, C. P. M. S., Cotrim, H. P., Stefano, J. T., Siqueira, A. C., Salgado, A. L. A., & Parise, E. R. (2019) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.201900000-36 · Cited by 38
Non-Alcoholic Fatty Liver Disease, an Overview.
Muhammad, A. (2019) · PubMed Central · Cited by 37
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH
Marchianò, S., Biagioli, M., Morretta, E., Giorgio, C. D., Roselli, R., Bordoni, M., Bellini, R., Urbani, G., Massa, C., Monti, M. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-28647-4 · Cited by 37
Management of Nonalcoholic Steatohepatitis
Mahady, S. E., & George, J. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.05.003 · Cited by 36
Nonalcoholic fatty liver disease: Diagnosis and relation to metabolic syndrome and approach to treatment
Lidofsky, S. D. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0006-1 · Cited by 36
Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway
Cho, I.-J., Oh, D.-H., Yoo, J. H., Hwang, Y., Ahn, K. J., Chung, H.-Y., Jeong, S. W., Moon, J.-Y., Lee, S. H., Lim, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88872-7 · Cited by 36
Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: A systematic review and meta-analysis
Lin, X., Mai, M., He, T., Huang, H., Zhang, P., Xia, E.-Q., & Guo, H. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2083605 · Cited by 37
Nonalcoholic Fatty Liver Disease: A Clinical Approach and Review
Raman, M., & Allard, J. P. (2006) · Canadian Journal of Gastroenterology · doi:10.1155/2006/918262 · Cited by 36
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 70
Nonalcoholic fatty liver
Malhi, H., Allen, A. M., & Watt, K. D. S. (2016) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000283 · Cited by 38
The Mexican consensus on nonalcoholic fatty liver disease
Bernal-Reyes, R., Castro‐Narro, G., Malé-Velázquez, R., Carmona-Sánchez, R., González-Huezo, M. S., García-Juárez, I., Chávez-Tapia, N. C., Aguilar-Salinas, C., Aiza-Haddad, I., Ballesteros-Amozurrutia, M. A., et al. (2019) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2019.02.003 · Cited by 35
Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis
Namisaki, T., Noguchi, R., Moriya, K., Kitade, M., Aihara, Y., Douhara, A., Nishimura, N., Takeda, K., Okura, Y., Kawaratani, H., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1104-x · Cited by 35
An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients
Parikh, P. M., Ingle, M., Patel, J., Bhate, P. A., Pandey, V. R., & Sawant, P. D. (2016) · Saudi Journal of Gastroenterology · doi:10.4103/1319-3767.182451 · Cited by 36
Pharmacological treatment of MASLD: contemporary treatment and future perspectives
Drygalski, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136518 · Cited by 39
Pharmacotherapy for Nonalcoholic Fatty Liver Disease
Gawrieh, S., & Chalasani, N. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562951 · Cited by 35
4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine—recommendations for facing obesity, fatty liver and fibrosis epidemics
Trovato, F. M., Catalano, D., Musumeci, G., & Trovato, G. M. (2014) · The EPMA Journal · doi:10.1186/1878-5085-5-21 · Cited by 35
Fatty Liver Disease
TINIAKOS, D. G., Anstee, Q. M., & Burt, A. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00005-4 · Cited by 35
Characterizing Fatty Liver in vivo in Rabbits, Using Quantitative Ultrasound
Nguyen, T., Podkowa, A. S., Tam, A. Y., Arnold, E. C., Miller, R. J., Park, T. H., Do, M. N., & Oelze, M. L. (2019) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2019.03.021 · Cited by 36
Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?
Lanthier, N., & Delzenne, N. M. (2022) · Cells · doi:10.3390/cells11172718 · Cited by 35
Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective
Luo, L., Chang, Y., & Li, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121614 · Cited by 33
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 34
Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions
Zhao, Q., Wu, J., Ding, Y., Pang, Y., & Jiang, C. (2023) · Life Metabolism · doi:10.1093/lifemeta/load032 · Cited by 31
The Role of Medications for the Management of Patients with NAFLD
Mazzella, N., Ricciardi, L. M., Mazzotti, A., & Marchesini, G. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.005 · Cited by 34
Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling
Marchianò, S., Biagioli, M., Roselli, R., Zampella, A., Giorgio, C. D., Bordoni, M., Bellini, R., Urbani, G., Morretta, E., Monti, M. C., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159218 · Cited by 36
Treatment of NASH with ursodeoxycholic acid: Pro
Ratziu, V. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/s2210-7401(12)70020-7 · Cited by 32
Non-alcoholic Steatohepatitis: An Overview
Shifflet, A., & Wu, G. Y. (2009) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60026-7 · Cited by 32
Treatment of preestablished diet-induced fatty liver by oral fatty acid–bile acid conjugates in rodents
Leikin-Frenkel, A. I., Goldiner, I., Leikin-Gobbi, D., Rosenberg, R. A., Bonen, H., Litvak, A., Bernheim, J., Konikoff, F. M., & Gilat, T. (2008) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3282fc9743 · Cited by 32
Nonalcoholic fatty liver disease (NAFLD): Approach in the adolescent patient
Roberts, E. A., & Yap, J. Y. K. (2006) · Current Treatment Options in Gastroenterology · doi:10.1007/bf02738532 · Cited by 31
Administration of Pancrelipase as Effective Treatment for Hepatic Steatosis After Pancreatectomy
Kishi, Y., Shimada, K., Nara, S., Esaki, M., & Kosuge, T. (2015) · Pancreas · doi:10.1097/mpa.0000000000000356 · Cited by 31
Meta‐analysis: analysis of mechanistic pathways in the treatment of non‐alcoholic steatohepatitis. Evidence from a Bayesian network meta‐analysis
Muthiah, M. D., Ng, C. H., Xiao, J., Chin, Y. H., Lim, G., Lim, W. H., Tay, P. W. L., Tan, D. J. H., Yong, J. N., Pan, X., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16808 · Cited by 32
Treating nonalcoholic fatty liver disease
Méndez‐Sánchez, N., Arrese, M. A., Zamora‐Valdés, D., & Uribe, M. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01567.x · Cited by 31
Evolving trends in nonalcoholic fatty liver disease
Delgado, J. (2008) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2007.02.034 · Cited by 31
Non‐Alcoholic Fatty Liver and Non‐Alcoholic Steatohepatitis
Farrell, G. C. (2007) · doi:10.1002/9780470691861.ch13 · Cited by 31
The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
Assi, R. A., Abdulbaqi, I. M., & Chan, S. Y. (2021) · Pharmaceuticals · doi:10.3390/ph14030215 · Cited by 33
A high-dose of ursodeoxycholic acid treatment alleviates liver inflammation by remodeling gut microbiota and bile acid profile in a mouse model of non-alcoholic steatohepatitis
Hu, L., Wang, M., Chen, P., Zhu, M., & Chen, L. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116617 · Cited by 30
Pathophysiology of Non-Alcoholic Steatohepatitis and Basis for Treatment
Pinzani, M. (2011) · Digestive Diseases · doi:10.1159/000323928 · Cited by 30
Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease.
Madan, K., Batra, Y., Gupta, D., Chander, B., Rajan, A., Singh, R., Panda, S. K., & Acharya, S. K. (2005) · PubMed · Cited by 30
Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future
Gitto, S., Vitale, G., Villa, E., & Andreoné, P. (2015) · Gastroenterology Research and Practice · doi:10.1155/2015/732870 · Cited by 30
Glycine prevents metabolic steatohepatitis in diabetic KK-Aymice through modulation of hepatic innate immunity
Takashima, S., Ikejima, K., Arai, K., Yokokawa, J., Kon, K., Yamashina, S., & Watanabe, S. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00465.2015 · Cited by 30
Serum Bile Acid Profiles Improve Clinical Prediction of Nonalcoholic Fatty Liver in T2DM patients
Wu, T., Yang, M. S., Xu, H., Wang, L., Wei, H., & Ji, G. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00104 · Cited by 31
Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety
Gianturco, V., Troisi, G., Bellomo, A., Bernardini, S., D’Ottavio, E., Formosa, V., Iacono, C. L., Verrusio, W., Marigliano, B., & Marigliano, V. (2012) · Hepatology International · doi:10.1007/s12072-012-9387-y · Cited by 30
NASH may be trash: Table 1
Cassiman, D. M., & Jaeken, J. (2008) · Gut · doi:10.1136/gut.2007.123240 · Cited by 30
Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Hung, C. K., & Bodenheimer, H. C. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.012 · Cited by 30
A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis
Adams, L. A., Angulo, P., Petz, J., Keach, J. C., & Lindor, K. D. (2010) · Hepatology International · doi:10.1007/s12072-010-9195-1 · Cited by 29
Self-citation
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Lee, H. A., Chang, Y. W., Sung, P. S., Yoon, E. L., Lee, H. W., Yoo, J., Lee, Y., An, J., Song, D. S., Cho, Y. Y., et al. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0186 · Cited by 31
The pharmacological management of NAFLD in children and adolescents
Liyanagedera, S., Williams, R. P., Veraldi, S., Nobili, V., & Mann, J. P. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1365599 · Cited by 30
NASH: a hidden and silent fibroser finally revealed?
Ratziu, V., & Poynard, T. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.027 · Cited by 29
Current management of non-alcoholic fatty liver disease
Lisboa, Q. C., COSTA, S. M. F., & Couto, C. A. (2016) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.62.09.872 · Cited by 28
Hepatic Complications of Obesity
Diehl, A. M. (2005) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2004.12.012 · Cited by 28
UDCA for NASH: End of the story?
Haedrich, M., & Dufour, J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.10.009 · Cited by 28
Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes
Misra, A., Kumar, A., Kuchay, M. S., Ghosh, A., Gulati, S., Choudhary, N. S., Dutta, D., Sharma, P., Vikram, N. K., Rastogi, A., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103209 · Cited by 27
Ursodeoxycholic acid dose‐dependently improves liver injury in rats fed a methionine‐ and choline‐deficient diet
Buko, V., Kuzmitskaya, I., Naruta, E. E., Lukivskaya, O., Kirko, S. N., & Tauschel, H. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00820.x · Cited by 27
Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease
Khullar, V., Dolganiuc, A., & Firpi, R. J. (2014) · World Journal of Transplantation · doi:10.5500/wjt.v4.i2.81 · Cited by 26
Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis
Roskilly, A., Hicks, A., Taylor, E., Jones, R. L., Parker, R., & Rowe, I. A. C. (2020) · Liver International · doi:10.1111/liv.14749 · Cited by 27
Fatty liver disease
Brunt, E. M., Neuschwander‐Tetri, B. A., & Burt, A. D. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00006-4 · Cited by 27
Therapeutic potential of bioactive phytoconstituents found in fruits in the treatment of non-alcoholic fatty liver disease: A comprehensive review
Pathak, M. P., Pathak, K., Saikia, R., Gogoi, U., Patowary, P., Chattopadhyay, P., & Das, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15347 · Cited by 28
Unfolded Protein Response Sensors in Hepatic Lipid Metabolism and Nonalcoholic Fatty Liver Disease
Henkel, A. S. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1670677 · Cited by 30
Nonalcoholic Steatohepatitis and the Cardiometabolic Syndrome
Abdeen, M. B., Chowdhury, N. A., Hayden, M. R., & Ibdah, J. A. (2006) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.0197-3118.2006.05523.x · Cited by 26
Effect of Alcohol on Viral Hepatitis and Other Forms of Liver Dysfunction
Balasubramanian, S., & Kowdley, K. V. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.10.004 · Cited by 26
Self-citation
State of the art
Pearlman, M. Y., & Loomba, R. S. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000060 · Cited by 25
Emerging drugs for non-alcoholic fatty liver disease
Federico, A., Niosi, M., Blanco, C. D. V., & Loguercio, C. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.1.145 · Cited by 25
The treatment of NAFLD.
Trappoliere, M., Tuccillo, C., Federico, A., Di Leva, A., Niosi, M., D’Alessio, C., Capasso, R., Coppola, F., D’Auria, M. V., & Loguercio, C. (2005) · PubMed · Cited by 25
Review: Non-alcoholic fatty liver disease: natural history, pathogenesis and treatment
McAvoy, N. C., Ferguson, J., Campbell, I. W., & Hayes, P. C. (2006) · The British Journal of Diabetes · doi:10.1177/14746514060060060201 · Cited by 26
Bile salt signaling and bile salt-based therapies in cardiometabolic disease
Groenen, C., Nguyen, T.-A., Paulusma, C. C., & van de Graaf, S. F. J. (2024) · Clinical Science · doi:10.1042/cs20230934 · Cited by 25
Efficacy and safety of drugs for nonalcoholic steatohepatitis
Shen, B., & Lu, L. (2021) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12967 · Cited by 24
The endoplasmic reticulum as a potential therapeutic target in nonalcoholic fatty liver disease.
Gentile, C. L., & Pagliassotti, M. J. (2008) · PubMed · Cited by 23
Non-alcoholic fatty liver disease: when to intervene and with what
Than, N. N., & Newsome, P. N. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-2-186 · Cited by 24
Treatment of nonalcoholic steatohepatitis with colestimide
Taniai, M., Hashimoto, E., Tobari, M., Yatsuji, S., Haruta, I., Tokushige, K., & Shiratori, K. (2009) · Hepatology Research · doi:10.1111/j.1872-034x.2009.00507.x · Cited by 24
Nonalcoholic Fatty Liver Disease
Sanyal, A. J. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.014 · Cited by 53
Nonalcoholic Fatty Liver Disease
Gawrieh, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-30103-7_14 · Cited by 25
Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
Tomasiewicz, K., Flisiak, R., Halota, W., Jaroszewicz, J., Lebensztejn, D. M., Lisik, W., Małkowski, P., Pawłowska, M., Piekarska, A., Simon, K. A., et al. (2018) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2018.78118 · Cited by 23
The Future of Nonalcoholic Fatty Liver Disease Treatment
Mazhar, K. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.08.005 · Cited by 24
Review: Advances in the treatment of nonalcoholic fatty liver disease
Mehta, S. R. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810379587 · Cited by 24
Bile Formation and the Enterohepatic Circulation
Dawson, P. A., Shneider, B. L., & Hofmann, A. F. (2006) · Elsevier eBooks · doi:10.1016/b978-012088394-3/50059-3 · Cited by 24
Effect of ursodeoxycholic acid supplementation on growth, carcass characteristics, and meat quality of Wagyu heifers (Japanese Black cattle)
Irie, M., KOUDA, M., & Matono, H. (2011) · Journal of Animal Science · doi:10.2527/jas.2011-4211 · Cited by 22
Nonalcoholic Fatty Liver Disease
Ko, J. S. (2010) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2010.56.1.6 · Cited by 24
Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis
Sridharan, K., Sivaramakrishnan, G., Sequeira, R. P., & Elamin, A. (2018) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2018-135967 · Cited by 22
Oxidative Stress in Nonalcoholic Fatty Liver Disease: Pathogenesis and Antioxidant Therapies
Gawrieh, S., Opara, E. C., & Koch, T. R. (2004) · Journal of Investigative Medicine · doi:10.1177/108155890405200822 · Cited by 22
Negative trials in nonalcoholic steatohepatitis: Why they happen and what they teach us
Clark, J. M., & Brancati, F. L. (2004) · Hepatology · doi:10.1002/hep.20121 · Cited by 22
The emerging significance of mitochondrial targeted strategies in NAFLD treatment
Zhang, T., Nie, Y., & Wang, J. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121943 · Cited by 21
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Associazione Italiana per lo Studio del Fegato (AISF), S. I. D. D. (. A. S. I. D. (. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01287-1 · Cited by 22
Nichtalkoholische Fettleber und Steatohepatitis
Wiegand, J., Mössner, J., & Tillmann, H. L. (2007) · Der Internist · doi:10.1007/s00108-006-1796-3 · Cited by 20
Quantitative analysis of hepatic fat fraction by single-breath-holding MR spectroscopy with T 2 correction: phantom and clinical study with histologic assessment
Hayashi, N., Miyati, T., Minami, T., Takeshita, Y., Ryu, Y., Matsuda, T., Ohno, N., Hamaguchi, T., Kato, K., Takamura, T., et al. (2012) · Radiological Physics and Technology · doi:10.1007/s12194-012-0191-0 · Cited by 20
Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment.
Stengel, J. Z., & Harrison, S. A. (2006) · Europe PMC (PubMed Central) · Cited by 20

Authors: Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P.
Affiliations: Mayo Clinic (US)
University of Washington (US)
Toronto Western Hospital (CA)
Mayo Clinic in Arizona (US)
Corresponding author: Lindor, Keith D.
ORCID: Lindor, Keith D.
Kowdley, Kris V.
Venue: Hepatology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2004-03
Volume: 39
Issue: 3
Pages: 770-778
ISSN: 0270-9139 (ISSN-L)
DOI: 10.1002/hep.20092
OpenAlex: W2139112405
Cited by: 727
References: 26
Citations by year: 2026: 6 · 2025: 18 · 2024: 18 · 2023: 18 · 2022: 19 · 2021: 26 · 2020: 21 · 2019: 27 · 2018: 26 · 2017: 24 · 2016: 33 · 2015: 45 · 2014: 30 · 2013: 40 · 2012: 44
FWCI: 35.12
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4201 d)
Locations: Hepatology (publishedVersion)
PubMed (publishedVersion)
Funders: Baylor University
Baylor University Medical Center
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords: ursodeoxycholic acid, nonalcoholic steatohepatitis, NASH treatment, liver histopathology, steatosis, necroinflammation, liver fibrosis, liver enzymes, placebo comparison, drug safety and tolerability
MeSH terms: Alanine Transaminase, Aspartate Aminotransferases, Cholagogues and Choleretics, Double-Blind Method, Fatty Liver, Fibrosis, Humans, Liver, Necrosis, Ursodeoxycholic Acid, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks